Bambevi
Bevacizumab biosimilar developed by Apotex. Reference product Avastin.
Brands by market: Bambevi (Canada) · Commercial partner or holder: Apotex · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDANot listed
HCSep 2021approved
CDSCONot listed
EDENot listed
Approved or registered in 1 of 7 markets
Connections
About Bambevi
Bambevi is Apotex's bevacizumab, approved in Canada in September 2021. Like Apotex's other biosimilars it is a Canadian product with no counterpart in the United States or Europe.
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union
Not listed by EMA.
MHRA
United Kingdom
Not listed by MHRA.
PMDA
Japan
Not listed by PMDA.
HC
Canada · Bambevi
Health CanadaApprovedBrand
Bambevi
Holder or applicant
Apotex INC
Pathway
Biosimilar biologic drug (Notice of Compliance)
Approved
Sep 2021
Application or permission
DIN 02520729, 02520737
Presentations
100, 400 mg
Source
S022 (Health Canada) · checked Sep 2026
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Bambevi holds an approval, these are the other bevacizumab biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| HC | 5 | Amgen (Mvasi), Biocon Biologics (Jobevne / Abevmy / Krabeva), Celltrion (Vegzelma), Pfizer (Zirabev), Samsung Bioepis (Aybintio) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Apotex: Aflivu, Denoza.
Chronology
- HCSep 2021Notice of Compliance, Health Canada
Sources
Planning bevacizumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.